Dao Tian Fu
Plus aucun poste en cours
Profil
Dao Tian Fu served as a Director and Vice President at Livzon Pharmaceutical Group, Inc. from 2014 to 2019.
Prior to that, he held Director positions at LungLife AI, Inc. and Zalicus, Inc. He was also a Director at EPIRUS Biopharmaceuticals, Inc. from 2014 to 2016.
Before joining Livzon Pharmaceutical Group, Inc., he was the General Manager at Livzon MABPharm Inc. from 2012 to 2019.
He was the Vice President of Research at Genzyme Corp.
and the Director of the Primedica Division at rEVO Biologics, Inc. from 1998 to 2001.
He also worked as a Manager of Quality Control and Research at Neose Pharmaceuticals, Inc. from 1992 to 1998.
In terms of education, Dr. Fu received his doctorate from Iowa State University in 1990 and his undergraduate degree from Shandong University in 1983.
Anciens postes connus de Dao Tian Fu
| Sociétés | Poste | Fin |
|---|---|---|
| REMEGEN CO., LTD. | President | 12/05/2023 |
| LIVZON PHARMACEUTICAL GROUP INC. | Director/Board Member | 27/09/2019 |
Livzon MABPharm Inc.
 Livzon MABPharm Inc. Pharmaceuticals: MajorHealth Technology Part of ZHU HAI Livzon Biologics Ltd., Livzon MABPharm Inc. researches, develops, and sells biopharmaceutical products and antibody drugs. The private company is based in Zhuhai, China. | Chief Executive Officer | 01/09/2019 |
| EPIRUS BIOPHARMACEUTICALS, INC. | Director/Board Member | 25/07/2016 |
| REVO BIOLOGICS INC | Corporate Officer/Principal | 01/01/2001 |
Formation de Dao Tian Fu
| Iowa State University | Doctorate Degree |
| Shandong University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| LIVZON PHARMACEUTICAL GROUP INC. | Health Technology |
| LUNGLIFE AI, INC. | Health Services |
| EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
| REMEGEN CO., LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Neose Pharmaceuticals, Inc. | |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Livzon MABPharm Inc.
Livzon MABPharm Inc. Pharmaceuticals: MajorHealth Technology Part of ZHU HAI Livzon Biologics Ltd., Livzon MABPharm Inc. researches, develops, and sells biopharmaceutical products and antibody drugs. The private company is based in Zhuhai, China. | Health Technology |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
